ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $46.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2017-02-24
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2015 was $46.00K, a 71.25% decline from fiscal 2014.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2014 was $160.00K, a 196.30% increase from fiscal 2013.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2013 was $54.00K, a 31.65% decline from fiscal 2012.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2012 was $79.00K, a 71.74% increase from fiscal 2011.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2015-12-31 | $46.00K 10-K · filed 2017-02-24 | |
| 2014-12-31 | $160.00K 10-K · filed 2017-02-24 | |
| 2013-12-31 | $54.00K 10-K · filed 2016-03-29 | |
| 2012-12-31 | $79.00K 10-K · filed 2015-03-27 | |
| 2011-12-31 | $46.00K 10-K · filed 2014-03-27 | $45.00K 10-K · filed 2013-03-28 |
| 2010-12-31 | $14.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |